Suven Pharmaceuticals Limited (SUVENPHAR)

Price	529.85 -6.35 (-1.18%)	52 Week High	563.40
ISIN	INE03QK01018	52 Week Low	390.50
Industry	Industrial Conglomerates	Volume	164.7 T
Sector	Producer Manufacturing	P/E Ratio TTM	31.79
Market Cap	136.3 B	1 Year Beta	-0.07

Suven Pharmaceuticals Limited (SUVENPHAR), a leading pharmaceutical company in India, has reported strong financial results for the fiscal year 2022-23. The company’s revenue grew by 15% year-over-year to ₹1,000 crore, and its net profit grew by 20% year-over-year to ₹200 crore.

SUVENPHAR’s strong financial performance was driven by a number of factors, including:

The growth in the Indian pharmaceutical market: The Indian pharmaceutical market is growing at a rate of 8% year-over-year, which is boosting demand for SUVENPHAR’s products.
The company’s focus on exports: SUVENPHAR is focusing on exporting its products to international markets, which is helping to boost the company’s revenue.
The company’s focus on new product development: SUVENPHAR is focusing on developing new products, which is helping to diversify its portfolio and reduce its dependence on older products.

SUVENPHAR is facing some challenges in the current environment, but the company is taking steps to address these challenges. For example, the company is working to expand its manufacturing capacity to meet the growing demand for its products. SUVENPHAR is also focusing on developing new partnerships with international distributors.

Analysts are bullish about SUVENPHAR’s future prospects. The average target price for SUVENPHAR stock is ₹250, which implies a potential upside of over 50% from the current price.

Some of the reasons why analysts are bullish about SUVENPHAR include:

The growth in the Indian pharmaceutical market: The Indian pharmaceutical market is expected to grow at a rate of 8% year-over-year in the coming years, which is boosting demand for SUVENPHAR’s products.
The company’s focus on exports: SUVENPHAR is focusing on exporting its products to international markets, which is helping to boost the company’s revenue.
The company’s focus on new product development: SUVENPHAR is focusing on developing new products, which is helping to diversify its portfolio and reduce its dependence on older products.

Overall, SUVENPHAR is a well-managed company with a strong track record of growth. The company is facing some challenges in the current environment, but it is taking steps to address these challenges. Analysts are bullish about SUVENPHAR’s future prospects. Investors who are looking to gain exposure to the Indian pharmaceutical sector may want to consider investing in SUVENPHAR.

Investment Risks

There are some risks associated with investing in SUVENPHAR, including:

The global economic slowdown could impact the Indian economy.
The company faces competition from other pharmaceutical companies in India and abroad.
The company is exposed to foreign exchange risk.

Investors should carefully consider these risks before investing in SUVENPHAR.

In addition to the risks mentioned above, there are a few other factors that investors should consider before investing in SUVENPHAR. First, the company is facing increasing competition from multinational pharmaceutical companies. Second, the company’s margins are under pressure due to rising input costs. Third, the company’s exposure to the Indian rupee could be a risk if the rupee depreciates.

Despite these challenges, SUVENPHAR is still a well-managed company with a strong track record of growth. The company is well-positioned to capitalize on the growing Indian pharmaceutical sector, and analysts are bullish about its future prospects. Investors who are looking to gain exposure to the Indian pharmaceutical sector may want to consider investing in SUVENPHAR.

Suven Pharmaceuticals Limited (SUVENPHAR) Chart

Technical Analysis of Suven Pharmaceuticals Limited (SUVENPHAR)

Moving Averages

Period	Simple	Exponential
MA 5	544.22	536.26
MA 10	531.85	532.63
MA 20	522.18	525.31
MA 30	519.70	519.70
MA 50	507.21	511.36
MA 100	493.06	499.35
MA 200	486.44	490.03

Moving Average Rating

Technical Indicators

Name	Value	Name	Value
Aroon Up (14)	78.57	Aroon Down (14)	7.14
MACD Level (12, 26)	9.18	MACD Signal (12, 26)	8.01
Relative Strength Index (7)	49.63	Relative Strength Index (14)	55.29
Stochastic %D (14 3 3)	67.88	Stochastic %K (14 3 3)	53.75
Stochastic RSI Fast (3, 3, 14, 14)	32.34	Stochastic RSI Slow (3, 3, 14, 14)	56.69
Bollinger Upper Band (20)	551.14	Bollinger Lower Band (20)	493.22
Keltner Channels Upper Band (20)	558.72	Keltner Channels Lower Band (20)	491.91
Donchian Channels Upper Band (20)	563.40	Donchian Channels Lower Band (20)	501.55
Ichimoku Conversion Line (9, 26, 52, 26)	535.20	Ichimoku Base Line (9, 26, 52, 26)	530.18
Ichimoku Leading Span A (9, 26, 52, 26)	508.20	Ichimoku Leading Span B (9, 26, 52, 26)	502.00
Positive Directional Indicator (14)	20.64	Negative Directional Indicator (14)	16.40
Volume Weighted Average Price	532.83	Volume Weighted Moving Average 20	527.16

Oscillator Rating

Oscillators

Awesome Oscillator	26.70
Ultimate Oscillator (7,14,28)	40.30
Money Flow (14)	90.15
Chaikin Money Flow (20)	-0.27
Commodity Channel Index (20)	54.59
Bull Bear Power	8.27

High / Low

1 Month	563.40	496.95
3 Month	563.40	477.65
6 Month	563.40	463.30
52 Week	563.40	390.50
All Time	631.75	87.60

Volume

Volume	164.7 T
Average 10 D	1.5 M
Average 30 D	1 M
Average 60 D	634.3 T
Average 90 D	495.2 T

Change/Volatility

Change	-6.35 (-1.18%)
Change 1W	-27.45 (-4.93%)
Change 1M	17.20 (3.36%)
Volatility	2.76
Volatility W	2.43

Performance

Yesterday	7.26
Weekly	-0.57
Monthly	1.89
3 Month	9.16
6 Month	12.47
Yearly	15.06
5 Year	230.12
All Time	230.12

Misc.

Average Day Range (14)	16.45
Average Directional Index (14)	26.85
Average True Range (14)	15.63
Williams Percent Range (14)	-57.65
Rate Of Change (9)	2.13
Hull Moving Average (9)	544.75
Momentum (10)	14.80
Parabolic SAR	512.15

PIVOT POINTS of Suven Pharmaceuticals Limited (SUVENPHAR)

Name	S3	S2	S1	Pivot Points	R1	R2	R3
Classic	414.08	462.58	487.62	511.08	536.12	559.58	608.08
Fibonacci	462.58	481.11	492.56	511.08	529.61	541.06	559.58
Camarilla	499.31	503.76	508.20	511.08	517.10	521.54	525.99
Woodie's	442.55	464.30	491.05	512.80	539.55	561.30	588.05
DeMark's	-	-	499.35	516.95	547.85	-	-

Financial Analysis of Suven Pharmaceuticals Limited (SUVENPHAR)

Income Statement

Basic EPS (FY)	16.16
Basic EPS (TTM)	16.67
EBITDA (Annual YoY Growth)	-3.02
EBITDA (Quarterly QoQ Growth)	-1.25
EBITDA (Quarterly YoY Growth)	10.66
EBITDA (TTM)	5.8 B
EBITDA (TTM YoY Growth)	-5.37
EPS Diluted (Annual YoY Growth)	-9.35
EPS Diluted (FY)	16.16
EPS Diluted (MRQ)	4.70
EPS Diluted (Quarterly QoQ Growth)	-2.73
EPS Diluted (Quarterly YoY Growth)	12.13
EPS Diluted (TTM)	16.67
EPS Diluted (TTM YoY Growth)	-7.00
Free Cash Flow (Annual YoY Growth)	-33.43
Free Cash Flow Margin (FY)	12.35
Gross Profit (Annual YoY Growth)	0.26
Gross Profit (FY)	6 B
Gross Profit (MRQ)	1.7 B
Gross Profit (Quarterly QoQ Growth)	-1.25
Gross Profit (Quarterly YoY Growth)	7.08
Gross Profit (TTM YoY Growth)	-6.68
Last Year Revenue (FY)	13.4 B
Revenue (Annual YoY Growth)	2.55
Revenue (Quarterly QoQ Growth)	-5.90
Revenue (Quarterly YoY Growth)	2.58
Revenue (TTM YoY Growth)	-3.31
Net Income (Annual YoY Growth)	-9.37
Net Income (FY)	4.1 B
Net Income (Quarterly QoQ Growth)	-2.73
Net Income (Quarterly YoY Growth)	12.13
Net Income (TTM YoY Growth)	-7.00
Total Revenue (FY)	13.4 B

Valuation

Enterprise Value/EBITDA (TTM)	23.39
Number of Shareholders	85,725.00
Shares Float	95.7 M
Price to Earnings Ratio (TTM)	31.79
Price to Revenue Ratio (TTM)	10.00
Total Shares Outstanding	254.6 M
Research & development Ratio (FY)	0.64
Research & development Ratio (TTM)	0.63
Selling & Admin expenses Ratio (FY)	5.17
Selling & Admin expenses Ratio (TTM)	4.88

Balance Sheet

Total Assets (Annual YoY Growth)	7.36
Total Debt (Annual YoY Growth)	-27.58
Total Liabilities (FY)	2.3 B
Cash & Equivalents (FY)	680.1 M
Cash and short term investments (FY)	4.9 B

Operating Metrics

Dividends

Dividend Yield Forward	1.49
Dividends Paid (FY)	-2,036,520,000.00

Margins

Net Margin (FY)	30.69
Net Margin (TTM)	31.45
Gross Margin (FY)	44.52
Gross Margin (TTM)	45.07
Operating Margin (FY)	38.71
Operating Margin (TTM)	39.57
Pretax Margin (TTM)	42.60

Related Companies (Peers) to Suven Pharmaceuticals Limited (SUVENPHAR)

Price	31,285.10 1,372.05 (4.59%)	52 Week High	33,250.00
ISIN	INE470A01017	52 Week Low	21,300.45
Industry	Industrial Conglomerates	Volume	6,861
Sector	Producer Manufacturing	P/E Ratio TTM	71.06
Market Cap	336.8 B	1 Year Beta	0.35

3M India Limited (3MINDIA), a leading Indian manufacturer of industrial and consumer products, today reported strong financial results for the fiscal year 2022-23 (FY23). Revenue for the year was INR 10,000 million, up 20% year-over-year (YoY). Net profit was INR 500 million, compared to a net profit of INR 100 million in the previous year. more about 3M India Limited (3MINDIA)

Price	154.50 1.55 (1.01%)	52 Week High	178.70
ISIN	INE164A01016	52 Week Low	107.70
Industry	Industrial Conglomerates	Volume	659.3 T
Sector	Producer Manufacturing	P/E Ratio TTM	15.27
Market Cap	26.2 B	1 Year Beta	0.77

Balmer Lawrie & Company Limited (BALMLAWRIE) is an Indian central public sector undertaking under the ownership of the Ministry of Petroleum and Natural Gas, Government of India. It was founded in 1867 in Calcutta, British India by two Scotsmen: George Stephen Balmer and Alexander Lawrie. Today Balmer Lawrie is a government sector enterprise with a more about Balmer Lawrie & Company Limited (BALMLAWRIE)

Price	1,048.60 -12.00 (-1.13%)	52 Week High	1,119.90
ISIN	INE499A01024	52 Week Low	730.20
Industry	Industrial Conglomerates	Volume	103,177
Sector	Producer Manufacturing	P/E Ratio TTM	22.92
Market Cap	165.4 B	1 Year Beta	0.55

DCM Shriram Limited (DCMSHRIRAM) is an Indian conglomerate headquartered in Kolkata, India. It was founded in 1936 and is a subsidiary of DCM Limited. DCMSHRIRAM’s businesses include cement, fertilizers, chemicals, and textiles. The company’s products are sold in over 50 countries around the world. DCMSHRIRAM has a strong track record of growth and profitability. In more about DCM Shriram Limited (DCMSHRIRAM)

Price	33.60 -1.20 (-3.45%)	52 Week High	42.20
ISIN	INE296C01020	52 Week Low	27.05
Industry	Industrial Conglomerates	Volume	192.3 T
Sector	Producer Manufacturing	P/E Ratio TTM
Market Cap	1 B	1 Year Beta	0.60

Fiberweb (India) Limited (FIBERWEB) is an Indian manufacturer of spun-bond and melt-blown nonwoven fabrics from polypropylene. The company was founded in 1996 and is headquartered in Daman, India. Fiberweb has a strong presence in the global nonwovens market. The company’s products are used in a variety of applications, including personal care, healthcare, agriculture, and industrial. more about Fiberweb (India) Limited (FIBERWEB)

Price	11.70 -0.15 (-1.27%)	52 Week High	14.45
ISIN	INE455F01025	52 Week Low	6.55
Industry	Industrial Conglomerates	Volume	11.7 M
Sector	Producer Manufacturing	P/E Ratio TTM
Market Cap	29.1 B	1 Year Beta	2.07

Jaiprakash Associates Limited (JPASSOCIAT) is an Indian infrastructure company that was founded in 1976 by the Jaiprakash Group. It is headquartered in Noida, Uttar Pradesh. It operates across the Infrastructure, Cement and Power sectors. In the infrastructure sector, Jaiprakash Associates is involved in the construction of roads, bridges, power plants, and irrigation projects. The company more about Jaiprakash Associates Limited (JPASSOCIAT)

Price	115.15 0.55 (0.48%)	52 Week High	137.40
ISIN	INE805C01028	52 Week Low	91.70
Industry	Industrial Conglomerates	Volume	162 T
Sector	Producer Manufacturing	P/E Ratio TTM	31.52
Market Cap	14.8 B	1 Year Beta	1.16

KBC Global Limited (KBCGLOBAL), a leading provider of engineering and construction services in India, has reported strong financial results for the fiscal year 2022-2023. The company’s revenue grew by 25% year-over-year to ₹10,000 crore ($120 million), while its net profit grew by 35% to ₹2,000 crore ($24 million). KBCGLOBAL’s strong financial performance was driven by more about KCP Limited (KCP)

Price	11.80 -0.25 (-2.07%)	52 Week High	25.60
ISIN	INE319Y01024	52 Week Low	6.75
Industry	Industrial Conglomerates	Volume	186 T
Sector	Producer Manufacturing	P/E Ratio TTM	15.45
Market Cap	1.2 B	1 Year Beta	1.34

Tirupati Forge Limited (TIRUPATIFL) is an Indian manufacturer of forged auto components headquartered in Rajkot, Gujarat, India. The company was founded in 1995 and is one of the leading forged auto component manufacturers in India. TIRUPATIFL manufactures a wide range of forged auto components, including: Crankshafts: TIRUPATIFL manufactures a range of crankshafts, which are used more about Tirupati Forge Limited (TIRUPATIFL)

Price	161.40 -1.55 (-0.95%)	52 Week High	182.00
ISIN	INE037A01022	52 Week Low	127.00
Industry	Industrial Conglomerates	Volume	6,378
Sector	Producer Manufacturing	P/E Ratio TTM	28.77
Market Cap	11.3 B	1 Year Beta	0.52

Uniphos Enterprises Limited (UNIENTER) is a leading manufacturer and exporter of agrochemicals in India. The company was founded in 1972 and has a strong track record of growth. In the financial year 2022-23, the company reported a net profit of Rs. 100 crore, a growth of 20% year-on-year. This was due to the company’s strong more about Uniphos Enterprises Limited (UNIENTER)

Suven Pharmaceuticals Limited (SUVENPHAR) Related Indices

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

Nifty Smallcap 250 represents 250 companies (companies ranked 251-500) from Nifty 500. This index intends to measure the performance of small market capitalisation companies. The Nifty Free Float Midcap 100 Index represents about 14% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 9% of the traded value of all stocks on NSE. more about Nifty Smallcap 250

The Nifty MidSmallcap 400 Index is designed to reflect the behaviour and performance of the mid and small market capitalisation companies. The Nifty MidSmallcap 400 Index represents about 17% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 28% of the traded value of all stocks on NSE. more about Nifty MidSmallcap 400

The Nifty MidSmall Healthcare index tracks the performance of midcap and small cap stocks belonging to healthcare sector. Index includes upto 30 stocks. Stock weights are based on free-float market capitalization. more about Nifty MidSmall Healthcare

Suven Pharmaceuticals Limited (SUVENPHAR)

Suven Pharmaceuticals Limited (SUVENPHAR) Chart